Upstream Bio (UPB) reported second-quarter 2026 financial results and updates on verekitug, its treatment candidate for severe inflammatory respiratory diseases. The company recorded a net loss of $39.7 million for the quarter ended June 30, 2026, compared with a net loss of $40.0 million a year earlier.
The company said it had $261.3 million in cash, cash equivalents and short-term investments as of June 30, 2026, expected to fund planned operations through 2027. Upstream Bio remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027.
- Collaboration revenue was $773,000 for the second quarter of 2026.
- Research and development expenses were $36.1 million, down from $37.9 million in the same period of 2025.
- General and administrative expenses were $7.1 million, compared with $7.4 million a year earlier.
- Enrollment was completed in the Phase 2 VENTURE trial in COPD with 481 participants, with data expected in the second half of 2027.
- Upstream Bio said End-of-Phase 2 interactions with the FDA for severe asthma and CRSwNP are on track.
$UPB Insider Trading Activity
$UPB insiders have traded $UPB stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $UPB stock by insiders over the last 6 months:
- AARON DEYKIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 1,789 shares for an estimated $13,764.
- MICHAEL GRAY (CFO and COO) has made 0 purchases and 2 sales selling 1,705 shares for an estimated $13,118.
- EVERETT RAND SUTHERLAND (Chief Executive Officer) sold 2,095 shares for an estimated $12,779
- ADAM HOUGHTON (Chief Business Officer) sold 700 shares for an estimated $4,270
- ALLISON AMBROSE (General Counsel) sold 477 shares for an estimated $2,909
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$UPB Hedge Fund Activity
We have seen 87 institutional investors add shares of $UPB stock to their portfolio, and 70 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 1,574,989 shares (-87.2%) from their portfolio in Q1 2026, for an estimated $14,174,901
- OMEGA FUND MANAGEMENT, LLC removed 1,326,293 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,936,637
- FEDERATED HERMES, INC. added 979,276 shares (+203169.3%) to their portfolio in Q1 2026, for an estimated $8,813,484
- ALTSHULER SHAHAM LTD removed 961,479 shares (-71.7%) from their portfolio in Q1 2026, for an estimated $8,653,311
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC removed 750,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,750,000
- PICTET ASSET MANAGEMENT HOLDING SA removed 733,431 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $5,075,342
- VESTAL POINT CAPITAL, LP removed 720,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,480,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
